primary biliary cholangitis

News

Ipsen crosses EU finish line with Alagille syndrome drug

After various twists and turns in the regulator path, Ipsen has secured EU approval for Kayfanda, its treatment for severe itching (pruritus) in patients with the rare liver disease Alagill

News

Advanz wins stay on EU revocation of Ocaliva license

There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU.

News

Advanz Pharma's bid to keep Ocaliva on EU market fails

The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary

News

PBC drug choices rise in US with OK for Gilead's seladelpar

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade.

News

Ipsen's Alagille drug backed by CHMP again, with new name

In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU –

News

FDA clears Ipsen’s primary biliary cholangitis drug

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (

Ipsen crosses EU finish line with Alagille syndrome drug

Advanz wins stay on EU revocation of Ocaliva license

Advanz Pharma's bid to keep Ocaliva on EU market fails

PBC drug choices rise in US with OK for Gilead's seladelpar

Ipsen's Alagille drug backed by CHMP again, with new name

FDA clears Ipsen’s primary biliary cholangitis drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

primary biliary cholangitis

Editor's Picks